Gijs Kooij, PhD, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, provides an overview of the epigenetic mechanisms associated with disrupted lipid mediators in multiple sclerosis (MS) patients. Current investigations are looking into the epigenetic mechanisms of the enzymes that produce the lipids to understand whether they are suppressed or more active. This will also clarify the increased levels of pro-inflammatory lipid mediators in MS patients and how to regulate the epigenetic mechanisms in favor of MS patients. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Gijs Kooji received grants from Biogen, Merck and Novartis.